Latest news with #TrailBio.com
Cision Canada
5 days ago
- Business
- Cision Canada
Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells
BEACHWOOD, Ohio, Aug. 5, 2025 /CNW/ -- Trailhead Biosystems, Inc. ( a biotechnology company advancing scalable human cell models derived from induced pluripotent stem cells (iPSCs), announces the commercial release of TrailBio ® Hematopoietic Progenitor Cells. These progenitor cells are derived from a single, well-characterized iPSC line using Trailhead's proprietary High-Dimensional Design-of-Experiments (HD-DoE ®) platform, providing researchers with a consistent, scalable, and ready-to-use tool for hematopoietic research. TrailBio ® Hematopoietic Progenitor Cells express key hematopoietic markers including CD34, CD43 and CD90. Functional characterization confirms their ability to form myeloid and erythroid colonies in colony-forming unit (CFU) assays, differentiate into multiple hematopoietic lineages and demonstrate hematopoietic commitment through transcriptomic profiling. Designed for applications such as hematopoietic disease modeling, drug screening and hematotoxicity studies, TrailBio ® Hematopoietic Progenitor Cells enable a reliable human model system that eliminates donor variability and supports reproducible results. "TrailBio ® Hematopoietic Progenitor Cells strengthen our portfolio by providing researchers with high-quality, human-relevant cellular models," said David Llewellyn, Chief Executive Officer of Trailhead Biosystems. "Their consistency and multipotency enable scientists to advance research in hematopoietic biology and therapeutic development." "These Hematopoietic Progenitor Cells deliver a dependable combination of purity, potency and versatility," said Angelica Gomes Ueltschy, Scientific Director at Trailhead Biosystems. "Their robust marker expression and multilineage differentiation capacity make them well suited for modeling blood disorders and evaluating therapeutic candidates." Cell characterization information and additional data can be found at About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE ®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio ® Hematopoietic Progenitor Cells join a growing portfolio of iPSC-derived human cell types designed to bridge the gap between discovery and clinical translation. Learn more about Trailhead Biosystems, TrailBio® Hematopoietic Progenitor Cells and HD-DoE® at For more information, please contact: Tim Mauk, Corporate Communications Trailhead Biosystems Email: [email protected] SOURCE Trailhead Biosystems Inc
Yahoo
23-07-2025
- Business
- Yahoo
Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons
BEACHWOOD, Ohio, July 23, 2025 /PRNewswire/ -- Trailhead Biosystems, Inc. ( a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells at scale for drug discovery and cell therapy, introduces TrailBio® A9 Dopaminergic Neurons, a powerful new tool available off-the-shelf for studying Parkinson's disease and other neurodegenerative conditions. A9 dopaminergic neurons play a critical role in movement regulation and are disproportionately affected in Parkinson's disease. Historically, researchers have lacked access to viable human models, relying instead on animal studies with limited relevance. With TrailBio® A9 Dopaminergic Neurons, scientists now have a human-specific platform to investigate disease mechanisms, develop therapies and accelerate drug discovery. "TrailBio® A9 Dopaminergic Neurons open new possibilities for Parkinson's research," said Dr. Jan Jensen, Chief Scientific Officer, Chief Technology Officer and founder of Trailhead Biosystems. "These cells enable researchers to study the vulnerabilities of A9 neurons, helping drive progress toward more effective treatments." "For decades, the lack of human A9 neurons has limited our ability to truly understand Parkinson's disease," added Dr. Nooshin Amini, Scientific Director at Trailhead Biosystems. "Now, with TrailBio® A9 Dopaminergic Neurons, researchers can directly study the exact cells that are most affected, offering hope for groundbreaking insights and future therapies." About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® A9 Dopaminergic Neurons represent one of many specialized human cell types emerging from this platform, with additional cell models expected in the near future. Learn more about Trailhead Biosystems, TrailBio® A9 Dopaminergic Neurons and HD-DoE® at For more information, please contact: Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
